BD's outgoing diagnostic solutions and biosciences catalog brought in about $3.4 billion in 2024 sales. It will include tests for infectious disease and cervical cancer screening, as well as flow ...

Waters and BD shareholders are set to split ownership of the new outfit at about 60-40, respectively, while BD will also receive about $4 billion in cash. (Getty Images) BD has found a new home for ...

BD (Becton, Dickinson and Company) has agreed to combine its biosciences and diagnostic solutions business with Waters Corporation, creating a new life science and diagnostics company. The agreement ...

Global medtech giant BD announced that it is adding capacity to its US-based footprint for the production of critical medical devices, including syringes, needles, and IV catheters. As part of the ...

Becton, Dickinson has introduced an AI cloud-based platform to unify all of its medical device data into one place. The BD Incada Connected Care Platform will go hand-in-hand with BD’s Pyxis Pro ...

Shares of medical technology company Becton, Dickinson and Company (NYSE:BDX) fell 4.2% in the morning session after RBC Capital initiated coverage on the company with a neutral 'Sector Perform' ...

On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...

BD (BDX), the MedTech firm also known as Becton, Dickinson, traded lower in the premarket on Monday despite posting better-than-expected financials for Q1 fiscal 2026, as its life sciences segment ...